LisaLancasterMD
Pulmonology • Nashville, TNCritical Care Medicine, Interstitial Lung Diseases, Sleep Medicine
Professor, Medicine, Vanderbilt University School of Medicine
Dr. Lancaster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1301 Medical Center Drive
Pulmonary Clinic, VUMC
Nashville, TN 37232Phone+1 615-322-5000- Is this information wrong?
Summary
- Dr. Lisa Lancaster is a pulmonologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center. She received her medical degree from Medical College of Georgia School of Medicine and has been in practice 24 years. She specializes in pulmonary medicine, interstitial lung disease, idiopathic pulmonary fibrosis, and sleep medicine and is experienced in transplant pulmonology, cystic fibrosis, and ILD clinical trials.
Education & Training
Vanderbilt University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1999
University of Tennessee (Nashville)Residency, Internal Medicine, 1993 - 1996
Medical College of Georgia at Augusta UniversityClass of 1993
Certifications & Licensure
TN State Medical License 1996 - 2025
AL State Medical License 2020 - 2020- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Nashville Lifestyles Magazine Castle Connolly, 2008, 2011, 2013-2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2012 Jul 16
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
- Join now to see all
Publications & Presentations
PubMed
- Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Sympo...Ganesh Raghu, Marya Ghazipura, Thomas R Fleming, Kerri I Aronson, Jürgen Behr, Kevin K Brown, Kevin R Flaherty, Ella A Kazerooni, Toby M Maher, Luca Richeldi, Joseph A...> ;American Journal of Respiratory and Critical Care Medicine. 2024 Mar 15
- 13 citationsPCSK6 and Survival in Idiopathic Pulmonary Fibrosis.Kaminski, N., Justin M Oldham, Richard J Allen, Jose M Lorenzo-Salazar, Philip L Molyneaux, Shwu-Fan Ma, Chitra Joseph, John S Kim, Beatriz Guillen-Guio, Tamara Hernán...> ;American Journal of Respiratory and Critical Care Medicine. 2023 Jun 1
- 5 citationsIdentification of a Genetic Susceptibility Locus for Idiopathic Pulmonary Fibrosis in the 16p Subtelomere Using Whole-Genome Sequencing.Lauren J Donoghue, Amy D Stockwell, Margaret Neighbors, Rebecca X Sheng, Ramanandan Prabhakaran, Paul J Wolters, Lisa H Lancaster, Jonathan A Kropski, Timothy S Blackw...> ;American Journal of Respiratory and Critical Care Medicine. 2023 Apr 1
- Join now to see all
Press Mentions
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast Was Well Tolerated at 320 Mg with Durable Improvement Shown in FVC and Across Multiple MeasuresApril 30th, 2023- Highest Dose Bexotegrast Found to Improve Lung Function in IPFJanuary 31st, 2023
- Envisia Test May Help Identify ILD Patients with Progressing DiseaseOctober 21st, 2022
- Join now to see all
Hospital Affiliations
Vanderbilt University Medical CenterNashville, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
